ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. NAME OF THE MEDICINAL PRODUCT

Fintepla 2.2 mg/mL oral solution

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each mL contains 2.2 mg of fenfluramine (as fenfluramine hydrochloride).

Excipient(s) with known effect

Glucose (maize): 0.627 mg/mL
Sodium ethyl para-hydroxybenzoate (E 215): 0.23 mg/mL
Sodium methyl para-hydroxybenzoate (E 219): 2.3 mg/mL
Sulfur dioxide (E 220): 0.000009 mg/mL

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Oral solution.

Clear, colourless, slightly viscous liquid, with a pH of 5.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Fintepla is indicated for the treatment of seizures associated with Dravet syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.

4.2 Posology and method of administration

Fintepla should be initiated and supervised by physicians with experience in the treatment of epilepsy.

Fintepla is prescribed and dispensed according to the Fintepla controlled access programme (see section 4.4).

Posology

**Paediatric (children aged 2 years and older) and adult populations**

<table>
<thead>
<tr>
<th>Table 1: Dosage recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>without</strong> stiripentol</td>
</tr>
<tr>
<td>Starting dose – first week</td>
</tr>
</tbody>
</table>
Day 7 - second week*  
0.2 mg/kg twice daily  
(0.4 mg/kg/day)  
Maintenance dose  
0.2 mg/kg twice daily  
(0.4 mg/kg/day)

Day 14 - Further titration as applicable*  
0.35 mg/kg twice daily  
(0.7 mg/kg/day)  
Not applicable

Maximal recommended dose  
26 mg  
(13 mg twice daily i.e.  
6.0 mL twice daily)  
17 mg  
(8.6 mg twice daily i.e.  
4.0 mL twice daily)

* For patients who are tolerating fenfluramine and require a further reduction of seizures. For patients requiring more rapid titration, the dose may be increased every 4 days.

If the calculated dose is 3.0 mL or less, the green printed 3 mL syringe should be used.  
If the calculated dose is more than 3.0 mL, the purple printed 6 mL syringe should be used.  
The calculated dose should be rounded to the nearest graduated increment.

Discontinuation of treatment

When discontinuing treatment, the dose should be decreased gradually. As with all anti-epileptic medicines, abrupt discontinuation should be avoided when possible to minimize the risk of increased seizure frequency and status epilepticus.

Special populations

Patients with renal impairment
There are no clinical data available in subjects with renal impairment.

Patients with hepatic impairment
There are no clinical data available in subjects with hepatic impairment.  
Administration to patients with moderate or severe liver impairment is not recommended.

Elderly
There are no data on the use of Fintepla in elderly patients.

Paediatric population
The safety and efficacy of Fintepla in children below 2 years of age has not yet been established. No data are available.

Method of administration

Fintepla is to be administered orally.  
Fintepla may be taken with or without food.  
Fintepla is compatible with commercially available gastric and nasogastric feeding tubes (see section 6.6).  
Fintepla contains a very limited amount of digestible carbohydrates and is compatible with a ketogenic diet.

4.3 Contraindications

Hypersensitivity to the active substance or any of the excipients listed in section 6.1.  
Aortic or mitral valvular heart disease.  
Pulmonary arterial hypertension.
Within 14 days of the administration of monoamine oxidase inhibitors due to an increased risk of serotonin syndrome.

4.4 Special warnings and precautions for use

Aortic or mitral valvular heart disease and pulmonary arterial hypertension

Because of reported cases of valvular heart disease that may have been caused by fenfluramine at higher doses used to treat adult obesity, cardiac monitoring must be performed using echocardiography. In the controlled clinical studies of fenfluramine for the treatment of Dravet syndrome, no valvular heart disease was observed.

Prior to starting treatment, patients must undergo an echocardiogram to establish a baseline prior to initiating treatment (see section 4.3) and exclude any pre-existing valvular heart disease or pulmonary hypertension.

Echocardiogram monitoring should be conducted every 6 months for the first 2 years and annually thereafter. If an echocardiogram indicates pathological valvular changes, a follow-up echocardiogram should be considered at an earlier timeframe to evaluate whether the abnormality is persistent. If pathological abnormalities on the echocardiogram are observed, it is recommended to evaluate the benefit versus risk of continuing fenfluramine treatment with the prescriber, caregiver, and cardiologist.

If treatment is stopped because of aortic or mitral valvular heart disease, appropriate monitoring and follow-up should be provided in accordance with local guidelines for the treatment of aortic or mitral valvular heart disease.

With past use in higher doses to treat adult obesity, fenfluramine was reported to be associated with pulmonary arterial hypertension. Pulmonary arterial hypertension was not observed in the clinical programme, but because of the low incidence of this disease, the clinical trial experience with fenfluramine is inadequate to determine if fenfluramine increases the risk for pulmonary arterial hypertension in patients with Dravet syndrome.

If echocardiogram findings are suggestive of pulmonary arterial hypertension, a repeat echocardiogram should be performed as soon as possible and within 3 months to confirm these findings. If the echocardiogram finding is confirmed suggestive of an increased probability of pulmonary arterial hypertension defined as “intermediate probability” by the 2015 European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Guidelines, it should lead to a benefit-risk evaluation of continuation of Fintepla by the prescriber, carer, and cardiologist. If the echocardiogram finding, after confirmation, suggests of a high probability of pulmonary arterial hypertension, as defined by the 2015 ESC and ERS Guidelines, it is recommended fenfluramine treatment should be stopped.

Decreased appetite and weight loss

Fenfluramine can cause decreased appetite and weight loss (see section 4.8). An additive effect on decreased appetite can occur when fenfluramine is combined with other anti-epileptic medicines, for example stiripentol. The decrease in weight appears to be dose related. Most subjects resumed weight gain over time while continuing treatment. The patient's weight should be monitored. A benefit risk evaluation should be undertaken prior to commencing treatment with fenfluramine in patients with a history of anorexia nervosa or bulimia nervosa.

Fintepla controlled access programme
A controlled access programme has been created to 1) prevent off-label use in weight management in obese patients and 2) confirm that prescribing physicians have been informed of the need for periodic cardiac monitoring in patients taking Fintepla.

**Somnolence**

Fenfluramine can cause somnolence.

Other central nervous system depressants, including alcohol, could potentiate the somnolence effect of fenfluramine (see sections 4.5 and 4.7).

**Suicidal behaviour and ideation**

Suicidal behaviour and ideation have been reported in patients treated with anti-epileptic medicines in several indications. A meta-analysis of randomised placebo-controlled trials with anti-epileptic medicines that did not include fenfluramine has shown a small increased risk of suicidal behaviour and ideation. The mechanism of this risk is not known, and the available data do not exclude the possibility of an increased risk for fenfluramine. Patients and caregivers of patients should be advised to seek medical advice should any signs of suicidal behaviour and ideation emerge.

**Serotonin syndrome**

As with other serotonergic agents, serotonin syndrome, a potentially life-threatening condition, may occur with fenfluramine treatment, particularly with concomitant use of other serotonergic agents (including SSRIs, SNRIs, tricyclic antidepressants, or triptans); with agents that impair metabolism of serotonin such as MAOIs; or with antipsychotics that may affect the serotonergic neurotransmitter systems (see sections 4.3 and 4.5).

Serotonin syndrome symptoms may include mental status changes (eg, agitation, hallucinations, coma), autonomic instability (eg, tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (eg, hyperreflexia, incoordination), and/or gastrointestinal symptoms (eg, nausea, vomiting, diarrhoea).

If concomitant treatment with fenfluramine and other serotonergic agents that may affect the serotonergic systems is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.

**Increased seizure frequency**

As with other anti-epileptic medicines, a clinically relevant increase in seizure frequency may occur during treatment with fenfluramine, which may require adjustment in the dose of fenfluramine and/or concomitant anti-epileptic medicines, or discontinuation of fenfluramine, should the benefit-risk be negative.

**Cyproheptadine**

Cyproheptadine is a potent serotonin receptor antagonist and may therefore decrease the efficacy of fenfluramine. If cyproheptadine is added to treatment with fenfluramine, patients should be monitored for worsening of seizures. If fenfluramine treatment is initiated in a patient taking cyproheptadine, fenfluramine’s efficacy may be reduced.

**Glaucoma**
Fenfluramine can cause mydriasis and can precipitate angle closure glaucoma. Discontinue therapy in patients with acute decreases in visual acuity. Consider discontinuation if there is ocular pain and another cause cannot be determined.

**Strong CYP1A2 or CYP2B6 inducers**

Co-administration with strong CYP1A2 inducers or CYP2B6 inducers may decrease fenfluramine plasma concentrations (see section 4.5). An increase in fenfluramine dosage should be considered when co-administered with a strong CYP1A2 or CYP2B6 inducer; the maximum daily dose should not be exceeded.

**Excipients**

This medicinal product contains sodium ethyl para-hydroxybenzoate (E 215) and sodium methyl para-hydroxybenzoate (E 219) which may cause allergic reactions (possibly delayed).

It also contains sulfur dioxide (E 220) which may rarely cause severe hypersensitivity reactions and bronchospasm.

Patients with rare glucose-galactose malabsorption should not take this medicinal product.

This medicinal product contains less than 1 mmol sodium (23 mg) per the maximum daily dose of 12 mL, that is to say essentially ‘sodium-free’.

This medicinal product contains glucose which may be harmful to the teeth.

**4.5 Interaction with other medicinal products and other forms of interaction**

**Pharmacodynamic interactions**

Pharmacodynamic interactions with other central nervous system depressants increase the risk of aggravated central nervous system depression. Examples of such depressants are other serotonergic agents (including SSRIs, SNRIs, tricyclic antidepressants, or triptans); agents that impair metabolism of serotonin such as MAOIs; or antipsychotics that may affect the serotonergic neurotransmitter systems (see sections 4.3 and 4.4).

**Pharmacokinetic interactions**

**Clinical studies**

*Effect of steady state stiripentol plus clobazam and/or valproate on fenfluramine*

At steady state in the Phase 3 studies, the co-administration of 0.2 mg/kg twice daily (0.4 mg/kg/day), maximum 17 mg/day, fenfluramine with a standard anti-epileptic medicine regimen of stiripentol plus clobazam and/or valproate, resulted in a 130% increase in fenfluramine AUC\(_{0-24}\) and a 60% decrease in norfenfluramine AUC\(_{0-24}\), as compared to 0.35 mg/kg twice daily (0.7 mg/kg/day), maximum 26 mg/day, fenfluramine without stiripentol (see section 4.2).

*Effect of steady state cannabidiol on fenfluramine*

Co-administration of a single 0.35 mg/kg dose of fenfluramine with repeated doses of cannabidiol increased the AUC\(_{0,INF}\) of fenfluramine by 59% and the C\(_{max}\) by 10%, and decreased the AUC\(_{0,INF}\) of norfenfluramine by 22% and the C\(_{max}\) by 33%, as compared to fenfluramine administered alone. Co-administration of a single 0.35 mg/kg dose of fenfluramine, with repeated doses of cannabidiol, did not affect the pharmacokinetics of cannabidiol, as compared to cannabidiol alone. No dose adjustment is necessary when fenfluramine is co-administered with cannabidiol.

*In vitro studies*
Co-administration with strong CYP1A2 inducers or CYP2B6 inducers may decrease fenfluramine plasma concentrations.

**Effect of fenfluramine on other medicinal products**
Co-administration of a single 0.7 mg/kg dose of fenfluramine, with a single dose of a stiripentol, clobazam, and valproic acid combination, did not affect the pharmacokinetics of stiripentol, nor the pharmacokinetics of clobazam or its N-desmethyl-metabolite norclobazam, nor the pharmacokinetics of valproic acid, as compared to the stiripentol, clobazam, and valproic acid combination alone.

**Effect of fenfluramine on CYP2D6 substrates**
*In vitro* studies indicate that fenfluramine may inhibit CYP2D6. It has been reported that steady-state desipramine concentrations increase approximately 2-fold with concomitant administration of fenfluramine. Co-administration of fenfluramine with CYP2D6 substrates may increase their plasma concentrations.

**Effect of fenfluramine on CYP2B6 and CYP3A4 substrates**
*In vitro* studies indicate that fenfluramine may induce CYP2B6 and may induce intestinal CYP3A4. Co-administration of fenfluramine with CYP2B6 substrates or CYP3A4 substrates may decrease their plasma concentrations.

**Effect of fenfluramine on MATE1 substrates**
*In vitro* studies indicate that norfenfluramine (major and pharmacologically active metabolite) may inhibit MATE1 at clinically relevant concentrations. Co-administration of fenfluramine with MATE1 substrates may increase their plasma concentrations.

4.6  Fertility, pregnancy, and lactation

**Pregnancy**

There are limited data (less than 300 pregnancy outcomes) from the use of fenfluramine in pregnant women.

Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity in the absence of paternal or maternal toxicity (see section 5.3).

As a precautionary measure, it is preferable to avoid the use of Fintepla during pregnancy.

**Breast-feeding**

It is unknown whether fenfluramine/metabolites are excreted in human milk. Available pharmacokinetic data in animals have shown excretion of fenfluramine/metabolites in milk (see section 5.3).

A risk to the suckling child cannot be excluded.

A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Fintepla therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

**Fertility**

No effects of fenfluramine on human fertility up to clinical doses of 104 mg/day were noted. However, animal studies suggest that Fintepla may possibly affect female fertility (see section 5.3).

4.7  Effects on ability to drive and use machines
Fintepla has moderate influence on the ability to drive and use machines because it may cause somnolence and fatigue. Patients should be advised not to drive or operate machinery until they have gained sufficient experience to gauge whether it adversely affects their abilities (see section 4.8).

### 4.8 Undesirable effects

#### Summary of the safety profile

The most commonly reported adverse reactions are decreased appetite (44.2%), diarrhoea (30.8%), pyrexia (25.6%), fatigue (25.6%), upper respiratory tract infection (20.5%), lethargy (17.5%), somnolence (15.4%), and bronchitis (11.6%).

#### Tabulated list of adverse reactions

Adverse reactions reported with fenfluramine in placebo-controlled clinical studies are listed in the table below by System Organ Class and frequency. Frequencies are defined as very common (≥1/10) or common (≥1/100 to <1/10).

<table>
<thead>
<tr>
<th>MedDRA System Organ Class</th>
<th>Very common</th>
<th>Common</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infections and infestations</td>
<td>Bronchitis</td>
<td>Ear infection</td>
</tr>
<tr>
<td></td>
<td>Upper respiratory tract infection</td>
<td></td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td>Decreased appetite</td>
<td></td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td>Lethargy</td>
<td>Abnormal behaviour</td>
</tr>
<tr>
<td></td>
<td>Somnolence</td>
<td>Irritability</td>
</tr>
<tr>
<td></td>
<td>Status epilepticus</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tremor</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Constipation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diarrhoea</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Vomiting</td>
<td></td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>Pyrexia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fatigue</td>
<td></td>
</tr>
<tr>
<td>Investigations</td>
<td>Blood glucose decreased</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Echocardiogram abnormal (trace regurgitation)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Weight decreased</td>
<td></td>
</tr>
<tr>
<td>Injury, poisoning, and procedural complications</td>
<td>Fall</td>
<td></td>
</tr>
</tbody>
</table>

#### Description of selected adverse reactions

**Long-term safety**

Fenfluramine was used by 330 patients in an open-label trial for up to 3 years. The most commonly reported adverse reactions were decreased appetite (18.8%), echocardiogram abnormal (trace regurgitation) (8.2%), weight decreased (6.1%) and abnormal behaviour (5.2%).

**Decreased appetite and weight loss**

Fenfluramine can cause decreased appetite and weight loss. In the controlled trials of children and young adults with Dravet syndrome 34.4% of fenfluramine-treated patients had decreased appetite, compared to 8.3% of patients on placebo and approximately 18.9% of fenfluramine-treated patients.
had a decrease in weight ≥7% from their baseline weight, compared to 2.4% of patients on placebo. The decreases in appetite and weight appeared to be dose related. Most subjects resumed weight gain over time while continuing fenfluramine treatment.

**Status epilepticus**
In the phase 3 clinical trials the observed frequency of status epilepticus was 2.4% in the placebo group and 6.6% in the fenfluramine group. There were no discontinuations due to status epilepticus.

**Echocardiographic safety assessments of valvular regurgitation**
The possible occurrence of valvular heart disease was evaluated in the placebo-controlled and open-label extension studies for up to 3 years duration.

No patient developed any valvular heart disease in the double-blind studies or during the open-label extension study with treatment up to 3 years duration. Trace mitral valve regurgitation was reported 17.9% of subjects in the 0.2 mg/kg/day group (n=7/39), 22.5% in the 0.7 mg/kg/day group (n= 9/40), 20.9% in the 0.4 mg/kg/day group (n=9/43) and in 9.5% in the placebo group (n= 8/84). Mild mitral regurgitation was reported in 2.3% of the 0.4 mg/kg/day group (n=1/43). Trace aortic regurgitation was reported in 7.9% of the subjects in the 0.7 mg/kg/day group (n= 3/40). However, trace and mild mitral regurgitation, and trace aortic regurgitation are all non-pathologic findings as defined by the 2015 ESC and ERS Guidelines. All of the incidences reported were transient.

**Reporting of suspected adverse reactions**
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

**4.9 Overdose**
Only limited data have been reported concerning clinical effects and management of overdose of fenfluramine. Agitation, drowsiness, confusion, flushing, tremor (or shivering), fever, sweating, abdominal pain, hyperventilation, and dilated non-reactive pupils were reported at much higher doses of fenfluramine than those included in the clinical trial program.

Reportedly, the treatment of fenfluramine intoxication should include gastric lavage. Vital functions should be monitored closely, and supportive treatment administered in case of convulsions, arrhythmias, or respiratory difficulties.

**5. PHARMACOLOGICAL PROPERTIES**

**5.1 Pharmacodynamic properties**
Pharmacotherapeutic group: antiepileptics, other antiepileptics; ATC code: N03AX26

**Mechanism of action**
Fenfluramine is a serotonin releasing agent, and thereby stimulates multiple 5-HT receptor sub-types through the release of serotonin. Fenfluramine may reduce seizures by acting as an agonist at specific serotonin receptors in the brain, including the 5-HT1D, 5-HT2A, and 5-HT2C receptors, and also by acting on the sigma-1 receptor. The precise mode of action of fenfluramine in Dravet syndrome is not known.

**Clinical efficacy**
**Children and young adults**

The effectiveness of fenfluramine in children and young adults with Dravet syndrome was evaluated in two randomised, multicentre, placebo-controlled studies.

Study 1 (N=119) was a 3-arm, multicentre, randomised, double-blind, parallel group, placebo-controlled study consisting of a 6-week baseline period followed by a 2-week titration period and a 12-week maintenance period for a total of 14 weeks treatment. Eligible patients were randomised 1:1:1 to one of two doses of fenfluramine (0.7 mg/kg/day or 0.2 mg/kg/day, maximum 26 mg/day) or placebo. The mean (standard deviation) age of patients enrolled in Study 1 was 9.0 (4.7) years, with a range of 2 to 18 years. The majority of patients were ≥6 years of age (73.9%) and the minority <6 years (26.1%), male (53.8%), and white (82.4%). All enrolled patients were inadequately controlled on at least one anti-epileptic medicine, with or without vagal nerve stimulation and/or ketogenic diet. Patients were taking between one and five anti-epileptic medicines at study entry. The most frequently used concomitant anti-epileptic medicines (≥25% overall) were valproate (59.6%), clobazam (58.8%), and topiramate (25.2%). In Study 1, the median baseline convulsive seizure frequency per 28 days was 34.0, 17.5, and 21.2 in the placebo, fenfluramine 0.2 mg/kg/day, and fenfluramine 0.7 mg/kg/day groups, respectively.

Study 2 (previously known as 1504) (N=87) was a 2-arm, multicentre, randomised, double-blind, parallel group, placebo-controlled study consisting of a 6-week baseline period followed by a 3-week titration period and a 12-week maintenance period for a total of 15 weeks treatment. Eligible patients were randomised 1:1 to fenfluramine 0.4 mg/kg/day (maximum 17 mg/day) or placebo added to their stable standard of care regimen of stiripentol (plus clobazam and/or valproate) and possibly other anti-epileptic medicines. The mean (standard deviation) age of patients enrolled in Study 2 was 9.1 (4.80) years, with a range of 2 to 19 years. The majority of patients were ≥6 years of age (72.4%) and the minority <6 years (27.6%), male (57.5%) and, where reported, white (59.8%). All enrolled subjects were inadequately controlled on at least one anti-epileptic medicine, which included stiripentol, with or without vagal nerve stimulation and/or ketogenic diet. The median baseline convulsive seizure frequency per 28 days was 10.7 and 14.3 in the placebo and fenfluramine 0.4 mg/kg/day groups, respectively.

**Table 3: Study 1 and Study 2 (previously known as 1504): results of primary and selected secondary efficacy endpoints**

<table>
<thead>
<tr>
<th></th>
<th>Study 1</th>
<th></th>
<th>Study 2</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo</td>
<td>Fenfluramine 0.2 mg/kg/day</td>
<td>Placebo + stiripentol</td>
<td>Fenfluramine 0.4 mg/kg/day + stiripentol</td>
</tr>
<tr>
<td><strong>Convulsive Seizure Frequency</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Maintenance period</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>N</strong></td>
<td>39</td>
<td>39</td>
<td>44</td>
<td>43</td>
</tr>
<tr>
<td><strong>Baseline. Median (min, max)</strong></td>
<td>34.0 (3.3, 147.3)</td>
<td>17.5 (4.8, 623.5)</td>
<td>21.2 (4.9, 127.0)</td>
<td>10.7 (2.7, 162.7)</td>
</tr>
<tr>
<td><strong>At end of maintenance period. Median (min, max)</strong></td>
<td>25.7 (3.6, 204.7)</td>
<td>17.1 (0.0, 194.3)</td>
<td>4.9 (0.7, 169.3)</td>
<td>3.9 (0.0, 518.0)</td>
</tr>
<tr>
<td><strong>Reduction in mean monthly baseline-adjusted Convulsive Seizure Frequency compared to</strong></td>
<td>-</td>
<td>36.7% p=0.016</td>
<td>67.3% p&lt;0.001</td>
<td>-</td>
</tr>
<tr>
<td>Study</td>
<td>Placebo</td>
<td>Fenfluramine 0.2 mg/kg/day</td>
<td>Fenfluramine 0.7 mg/kg/day</td>
<td>Placebo + stiripentol</td>
</tr>
<tr>
<td>----------</td>
<td>---------</td>
<td>----------------------------</td>
<td>----------------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td><strong>% reduction in convulsive seizures</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maintenance period</td>
<td>Placebo</td>
<td>Fenfluramine 0.2 mg/kg/day</td>
<td>Fenfluramine 0.7 mg/kg/day</td>
<td>Placebo + stiripentol</td>
</tr>
<tr>
<td>Number (%) of patients with ≥50% reduction in monthly convulsive seizures - change from baseline</td>
<td>4 (10.3%)</td>
<td>17 (43.6%)</td>
<td>29 (72.5%)</td>
<td>4 (9.1%)</td>
</tr>
<tr>
<td>Effect size</td>
<td>ES=33.3%</td>
<td>ES=62.2%</td>
<td>ES=62.2%</td>
<td>ES=45.7%</td>
</tr>
<tr>
<td>Number (%) of patients with ≥75% reduction in monthly convulsive seizures - change from baseline</td>
<td>2 (5.1%)</td>
<td>10 (25.6%)</td>
<td>21 (52.5%)</td>
<td>2 (4.5%)</td>
</tr>
<tr>
<td>Effect size</td>
<td>ES=20.5%</td>
<td>ES=47.4%</td>
<td>ES=47.4%</td>
<td>ES=36.0%</td>
</tr>
<tr>
<td>Relative Risk</td>
<td>RR: 5.00</td>
<td>RR: 10.24</td>
<td>RR: 10.24</td>
<td>RR: 8.90</td>
</tr>
<tr>
<td>Number (%) of patients with ≥100% reduction in monthly convulsive seizures - change from baseline</td>
<td>0 (0%)</td>
<td>6 (15.4%)</td>
<td>6 (15.0%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Effect size</td>
<td>ES=15.4%</td>
<td>ES=15.0%</td>
<td>ES=15.0%</td>
<td>ES=4.8%</td>
</tr>
<tr>
<td>Longest seizure-free interval (median)</td>
<td>9.5 days</td>
<td>15.0 days p=0.035</td>
<td>25.0 days p&lt;0.001</td>
<td>13.0 days</td>
</tr>
</tbody>
</table>

1 Effect size (ES) (Risk difference) calculated as proportion of Active-Placebo; RR: Relative Risk

**Adults**

The Dravet syndrome population in Study 1 and Study 2 was predominantly paediatric patients, with only 7 adult patients who were 18-19 years old (3.4%), and therefore limited efficacy and safety data were obtained in the adult Dravet syndrome population.

**Open-label data**

Patients who participated in Study 1 and Study 2 could participate in an open-label extension study. The primary objective of the open-label study was long-term effectiveness and safety of fenfluramine at doses of 0.2 to 0.7 mg/kg/day, whereby the dose of fenfluramine could be titrated to optimize treatment. Data are reported for 330 patients who participated in the open-label study and received fenfluramine for up to 3 years (median treatment period: 631 days; range: 7-1086). A total of 23% of subjects discontinued study participation during the open-label extension treatment period, including 15% due to lack of efficacy and 1% due to adverse events.
Paediatric population

The European Medicines Agency has deferred the obligation to submit the results of studies with Fintepla in one or more subsets of the paediatric population in Dravet syndrome (see section 4.2 for information on paediatric use).

5.2 Pharmacokinetic properties

Pharmacokinetics

The pharmacokinetics of fenfluramine and norfenfluramine were studied in healthy subjects and in paediatric patients with Dravet syndrome.

Absorption

For fenfluramine, the $C_{\text{max}}$ occurs ~3 h following a single oral dose in healthy volunteers and is 28.6 ng/mL following a dose of 0.35 mg/kg and 59.3 ng/mL following a dose of 0.7 mg/kg fenfluramine. The $AUC_{\text{inf}}$ is 673 ng × h/mL and 1660 ng × h/mL following 0.35 mg/kg and 0.7 mg/kg, respectively. For norfenfluramine, the $C_{\text{max}}$ occurs ~12 h following a single oral dose in healthy volunteers and is 11.7 ng/mL and 16.1 ng/mL following a dose of 0.354 mg/kg or 0.78 mg/kg, respectively. The $AUC_{\text{inf}}$ is 798 ng × h/mL and ~800 ng × h/mL following 0.35 mg/kg and 0.7 mg/kg, respectively. $C_{\text{max}}$ and $AUC_{\text{inf}}$ of fenfluramine appear dose proportional over the 0.35 to 0.7 mg/kg dose range in healthy volunteers. The $C_{\text{max}}$ and $AUC_{\text{inf}}$ of norfenfluramine are less than dose proportional over the 0.35 to 0.7 mg/kg dose range in healthy volunteers. The $AUC_{\text{inf}}$ increase was 0.5-fold for the 0.7 mg/kg dose compared to the 0.35 mg/kg dose. The $C_{\text{max}}$ increase was 0.7-fold for the 0.7 mg/kg dose compared to the 0.35 mg/kg dose.

In paediatric patients following fenfluramine dosing of 0.2 mg/kg/day, administered twice daily, steady state exposure ($AUC_{0-24}$) is 371 ng*h/mL for fenfluramine and 222 ng*h/mL for norfenfluramine. In paediatric patients following fenfluramine dosing of 0.7 mg/kg/day, administered twice daily with a maximum of 26 mg/day; steady state $AUC_{0-24}$ is 1400 ng*h/mL for fenfluramine and 869 ng*h/mL for norfenfluramine following a dose of 0.7 mg/kg/day, administered twice daily. $C_{\text{max,ss}}$ was 68.6 ng/mL for fenfluramine and 37.8 ng/mL for norfenfluramine. When stiripentol is given concomitantly, the steady state $AUC_{0-24}$ is 1030 ng*h/mL for fenfluramine and 139 ng*h/mL for norfenfluramine following a dose of 0.2 mg/kg/day, administered twice daily; the steady state $AUC_{0-24}$ is 3240 ng*h/mL for fenfluramine and 364 ng*h/mL for norfenfluramine following a dose of 0.35 mg/kg/day, administered twice daily.

The absolute bioavailability of fenfluramine is approximately 75-83%. There was no effect of food on the pharmacokinetics of fenfluramine or norfenfluramine.

The plasma half-life of fenfluramine and norfenfluramine indicates that approximately 94% of steady-state would be reached in approximately 4 days for fenfluramine and 5 days for norfenfluramine (4 half-lives). In healthy subjects, the $C_{\text{max}}$ accumulation ratio is 3.7-fold for fenfluramine and 6.4-fold for norfenfluramine and the $AUC_{0-24}$ accumulation ratio is 2.6-fold for fenfluramine and 3.7-fold for norfenfluramine.

Distribution

Fenfluramine is 50% bound to human plasma proteins in vitro and binding is independent of fenfluramine concentrations. The geometric mean (CV%) volume of distribution (Vd/F) of fenfluramine is 11.9 (16.5%) L/kg following oral administration of fenfluramine in healthy subjects.

Biotransformation
Over 75% of fenfluramine is metabolised to norfenfluramine prior to elimination, primarily by CYP1A2, CYP2B6, and CYP2D6. Norfenfluramine is then deaminated and oxidized to form inactive metabolites. The extent to which these inactive metabolites are present in plasma and urine is unknown. The involvement of enzymes other than CYPs (e.g. UGTs) in the metabolism of norfenfluramine is unknown, but literature data indicate that norfenfluramine may be glucuronidated to a significant extent.

**Transporters**

Fenfluramine and norfenfluramine were not in vitro substrates of P-glycoprotein, BCRP, OATP1B1, OATP1B3, OATP1A2, OATP2B1, OCT1, OAT1, OAT3, OCT2, MATE1 and MATE2-K.

**Elimination**

Most of an orally administered dose of fenfluramine (>90%) is excreted in the urine mainly as metabolite; less than 5% is found in faeces. The geometric mean (CV%) clearance (CL/F) of fenfluramine is 6.9 L/h (29%) and the half-life is 20 hours following oral administration of fenfluramine in healthy subjects. The elimination half-life of norfenfluramine is ~30 h.

**Special populations**

**Genetic polymorphisms**

No impact of genotype in CYP1A2, CYP2B6, CYP2C19, CYP2D6, or CYP3A4 on fenfluramine or norfenfluramine PK was observed.

**Renal impairment**

Renal elimination is the predominant route of elimination of fenfluramine-related products, with more than 90% of the administered dose eliminated in the urine as parent or metabolites. There are no human clinical data on the effect of renal impairment on the PK of fenfluramine and norfenfluramine.

**Hepatic impairment**

No studies on the effect of hepatic impairment on the PK of fenfluramine in adults or children were found. With hepatic metabolism of fenfluramine, plasma drug concentrations may be affected in patients with significant hepatic impairment. Subjects with moderate or severe hepatic impairment were excluded from the phase 3 clinical trials.

**Body weight**

Drug clearance and PK exposure of fenfluramine and norfenfluramine are consistent across a broad range of BMI (12.3 to 35 kg/m2).

**Gender**

The pharmacokinetics of fenfluramine and norfenfluramine were consistent between males and females.

**Race**

The evaluation was limited by the small sample size of non-white subjects that no conclusion on the effect of race on the pharmacokinetics can be made. The genetic polymorphs of the enzymes that metabolize fenfluramine are similar across races, only their frequency differs. Thus, although the mean exposure may differ slightly depending on race, the range of exposure would be expected to be similar.

### 5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity or genotoxicity. Knowledge of potential long-term toxicity including carcinogenic potential is however still limited.
In a lactation study, rats were dosed orally with radiolabeled dexfenfluramine at 1.2 mg/kg, and samples of plasma and milk were collected over 24 hours following the dose. Both dexfenfluramine and nordexfenfluramine were found in milk at 2 hours after dosing and levels declined over 24 hours. No dexfenfluramine was found in the milk at 24 hours. Nordexfenfluramine was present in small amounts at 24 hours. The radioactivity milk:plasma ratio was 9 ± 2 at 2 hours and 5 ± 1 at 24 hours. Based on a bodyweight comparison, the human equivalent dose (0.2 mg/kg dexfenfluramine) is less than the maximum recommended human dose of Fintepla.

Reproduction and development

Fenfluramine and norfenfluramine crossed the placenta in pregnant rats and rabbits. Plasma exposures were higher in rat foetuses than in the dams, while plasma exposures in rabbits were comparable between does and foetuses; however the effects in human foetuses are unknown.

In an embryofoetal development study in rats, decreased foetal body weight and increased incidences of external and skeletal malformations were observed at the high dose level in association with maternal toxicity. No foetal abnormalities were noted at exposures at least five-fold the plasma AUC in humans administered the maximum recommended therapeutic dose of Fintepla.

No fenfluramine-related external, visceral or skeletal malformations or variations were determined in an embryofoetal development study in rabbits but increased post-implantation losses were evident at all doses secondarily to fenfluramine maternal toxicity (body weight loss and decreased food consumption). Additional clinical signs of dilated pupils and increased respiration rate and tremors were observed. Plasma exposures (AUC) in rabbits were below those in humans at the maximum recommended therapeutic dose of Fintepla.

In a pre- and post-natal study in rats, maternal toxicity was associated with an increase in stillbirths at the high dose. No adverse effects on the F₀ and F₁ generations were confirmed at five-fold higher plasma exposures (AUC) than in humans at the maximum recommended therapeutic dose of Fintepla. In the first generation of offspring, there were no effects on overall reproductive function.

Fenfluramine did not affect the reproductive performance of male rats. In female rats, a reduction in the fertility index (defined by the proportion of matings that resulted in pregnancies) was observed at maternally toxic doses that correlated with less corpora lutea, significantly fewer implantation sites and a higher percentage of pre- and post-implantation losses. No effects on the fertility index were noticed at plasma exposures (AUC) approximately equivalent to those in humans at the maximum recommended therapeutic dose of Fintepla.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Sodium ethyl para-hydroxybenzoate (E 215)
Sodium methyl para-hydroxybenzoate (E 219)
Sucrose (E 955)
Hydroxyethylcellulose (E 1525)
Monosodium phosphate (E 339)
Disodium phosphate (E 339)
Cherry flavouring powder:
  Acacia (E 414)
  Glucose (maize)
  Ethyl benzoate
  Natural flavouring preparations
  Natural flavouring substances
  Flavouring substances
Maltodextrin (maize)  
Sulfur dioxide (E 220)  
Potassium citrate (E 332)  
Citric acid monohydrate (E 330)  
Water for injections

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

4 years.

Shelf life after first opening

This medicinal product should be used within 3 months of first opening the bottle.

6.4 Special precautions for storage

This medicinal product does not require any special storage conditions. Do not refrigerate or freeze.

6.5 Nature and contents of container

Fintepla is presented in a white High Density Polyethylene (HDPE) bottle with a child-resistant, tamper-evident cap packaged in a carton, a Low Density Polyethylene (LDPE) press-in bottle adaptor, and Polypropylene (PP)/HDPE oral syringes. The oral syringe included in the pack should be used to administer the prescribed dose.

Presentations:

Bottle containing 60 mL oral solution, a bottle adaptor, two 3 mL oral syringes with 0.1 mL graduations, and two 6 mL syringes with 0.2 mL graduations.
Bottle containing 120 mL oral solution, a bottle adaptor, two 3 mL oral syringes with 0.1 mL graduations, and two 6 mL syringes with 0.2 mL graduations.
Bottle containing 250 mL oral solution, a bottle adaptor, two 3 mL oral syringes with 0.1 mL graduations, and two 6 mL syringes with 0.2 mL graduations.
Bottle containing 360 mL oral solution, a bottle adaptor, two 3 mL oral syringes with 0.1 mL graduations, and two 6 mL syringes with 0.2 mL graduations.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Inserting the bottle adaptor:

When the bottle is first opened the bottle adaptor must be pushed into the bottle.  
Wash and dry hands.  
Remove the bottle adaptor packaging.  
Place the bottle on a flat, firm surface.  
Open the bottle.  
Hold the bottle firmly.  
Align the bottle adaptor with the open top of the bottle.
Push the bottle adaptor into the bottle using the palm of the hand.
The bottle adaptor should be flush with the top of the bottle.
The bottle adaptor should not be removed after each use.
The bottle cap can be screwed onto the bottle with the bottle adaptor in place.

**Cleaning the syringe:**

Separate the plunger from the syringe to rinse each part.
Rinse the oral syringe with clean water and allow it to air dry after each use.
Rinse the inside of the syringe and the plunger.
The syringe and plunger can be cleaned in a dishwasher.
Clean water can be pulled into the syringe with the plunger and pushed out several times to clean the syringe.
The syringe and plunger must be completely dry before the next use.

**Feeding tubes**

Fintepla oral solution is compatible with most enteral feeding tubes.
To flush the feeding tube, fill the syringe used for dosing with water and flush the tube. Do this 3 times.

7. **MARKETING AUTHORISATION HOLDER**

Zogenix ROI Limited,
Trinity House,
Charleston Road,
Ranelagh,
Dublin 6,
D06 C8X4
Ireland

8. **MARKETING AUTHORISATION NUMBER(S)**

EU/1/20/1491/001
EU/1/20/1491/002
EU/1/20/1491/003
EU/1/20/1491/004

9. **DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 18 December 2020

10. **DATE OF REVISION OF THE TEXT**

ANNEX II

A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer(s) responsible for batch release

Millmount Healthcare Ltd,
Millmount Site, Block 7,
City North Business Campus,
Stamullen,
Co. Meath,
K32 YD60
Ireland
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

• Periodic safety update reports (PSURs)

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder (MAH) shall submit the first PSUR for this product within 6 months following authorisation.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

• Risk management plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:
• At the request of the European Medicines Agency;
• Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

• Additional risk minimisation measures

Prior to launch of Fintepla in each Member State (MS), the marketing authorisation holder (MAH) must agree about the content and format of the educational materials (EM) and the controlled access programme (CAP) including communication media, distribution modalities and any other aspects of the programme, with the National Competent Authorities (NCA).
The MAH shall ensure that, in each MS where Fintepla is marketed, a CAP is implemented to prevent off-label use for weight management in obese patients, since the benefit-risk ratio in this population is known to be negative.

In addition, the CAP shall be implemented to confirm that prescribing physicians have been informed of the need for periodic cardiac monitoring in patients taking Fintepla due to the potential risk of valvular heart disease and pulmonary arterial hypertension.

The MAH shall ensure that in each MS where Fintepla is marketed, all healthcare professionals who are expected to prescribe the product are aware of the CAP and are provided with the educational package consisting of:

- Summary of product characteristics (SmPC)
- HCP guide

The educational material for healthcare professionals (HCP guide) shall address the following risks:

- Valvular heart disease (VHD)
- Pulmonary arterial hypertension (PAH)
- Off-label use for weight management

The HCP guide shall contain the following key messages:

- Brief information about the historical background on fenfluramine and its market withdrawal due to the risks of VHD and PAH.
- Emphasis that the currently approved indication has to be strictly adhered to and access is therefore controlled ensuring proper information of physicians before prescribing.
- Informing physicians about the conditions of the Fintepla Controlled Access Programme (that are agreed on national level).
- Instruction on detection, monitoring, and/or proper management of VHD and PAH associated with fenfluramine.
- Advice to encourage patients/carers to enrol patients in the fenfluramine registry to collect long-term safety data.

The educational material for patients and/or caregivers should address the following risks:

- Valvular heart disease (VHD)
- Pulmonary arterial hypertension (PAH)

The patient/carer guide shall contain the following key messages:

- Information about the importance of periodic cardiac monitoring (ECHOs)
- Education about the detection and proper management of VHD and PAH associated with fenfluramine.
- Encouragement to participate in the fenfluramine registry to collect long-term safety data.

- **Obligation to conduct post-authorisation measures**

The MAH shall complete, within the stated timeframe, the below measures:

<table>
<thead>
<tr>
<th>Description</th>
<th>Due date</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fintepla Registry on long-term safety</strong></td>
<td></td>
</tr>
<tr>
<td>The MAH shall perform an observational registry to provide data on long-term safety of fenfluramine in routine practice, with a focus on characterising and quantifying the important potential risks VHD and PAH (primary objective), and growth retardation (secondary objective). In addition, data on the frequency of echocardiographic monitoring will contribute to assess the effectiveness of risk minimisation measures.</td>
<td>Final report: October 2031</td>
</tr>
</tbody>
</table>
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
**PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING**

**Outer carton**

<table>
<thead>
<tr>
<th>1. NAME OF THE MEDICINAL PRODUCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fintepla 2.2 mg/mL oral solution</td>
</tr>
<tr>
<td>fenfluramine</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. STATEMENT OF ACTIVE SUBSTANCE(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Each mL contains 2.2 mg fenfluramine (as hydrochloride)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. LIST OF EXCIPIENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Excipients:</td>
</tr>
<tr>
<td>E 215, E 219</td>
</tr>
<tr>
<td>Cherry flavouring (glucose, E 220)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. PHARMACEUTICAL FORM AND CONTENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral solution</td>
</tr>
<tr>
<td>Bottle of 60 mL, bottle adaptor, two 3 mL oral syringes, and two 6 mL oral syringes</td>
</tr>
<tr>
<td>Bottle of 120 mL, bottle adaptor, two 3 mL oral syringes, and two 6 mL oral syringes</td>
</tr>
<tr>
<td>Bottle of 250 mL, bottle adaptor, two 3 mL oral syringes, and two 6 mL oral syringes</td>
</tr>
<tr>
<td>Bottle of 360 mL, bottle adaptor, two 3 mL oral syringes, and two 6 mL oral syringes</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. METHOD AND ROUTE(S) OF ADMINISTRATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Read the package leaflet before use.</td>
</tr>
<tr>
<td>Oral use.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keep out of the sight and reach of children.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>7. OTHER SPECIAL WARNING(S), IF NECESSARY</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>8. EXPIRY DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>

Use within 3 months of first opening the bottle.
Date of first bottle opening: __ / __ / ____

9. SPECIAL STORAGE CONDITIONS

Do not refrigerate or freeze.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Zogenix ROI Limited
Trinity House
Charleston Road
Ranelagh
Dublin 6
D06 C8X4
Ireland

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/20/1491/001 60 mL oral solution
EU/1/20/1491/002 120 mL oral solution
EU/1/20/1491/003 250 mL oral solution
EU/1/20/1491/004 360 mL oral solution

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Fintepla

17. UNIQUE IDENTIFIER – 2D BARCODE

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING

Bottle

1. NAME OF THE MEDICINAL PRODUCT

Fintepla 2.2 mg/mL oral solution
fenfluramine

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each mL contains 2.2 mg fenfluramine (as hydrochloride)

3. LIST OF EXCIPIENTS

Excipients:
E 215, E 219
Cherry flavouring (glucose, E 220)

4. PHARMACEUTICAL FORM AND CONTENTS

Oral solution

Bottle of 60 mL, bottle adaptor, two 3 mL oral syringes, and two 6 mL oral syringes
Bottle of 120 mL, bottle adaptor, two 3 mL oral syringes, and two 6 mL oral syringes
Bottle of 250 mL, bottle adaptor, two 3 mL oral syringes, and two 6 mL oral syringes
Bottle of 360 mL, bottle adaptor, two 3 mL oral syringes, and two 6 mL oral syringes

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.

Oral use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

Use within 3 months of first opening the bottle.
Date of first bottle opening: __ / __ / ____

9. **SPECIAL STORAGE CONDITIONS**

Do not refrigerate or freeze.

10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Zogenix ROI Limited  
Trinity House  
Charleston Road  
Ranelagh  
Dublin 6  
D06 C8X4  
Ireland

12. **MARKETING AUTHORISATION NUMBER(S)**

EU/1/20/1491/001 60 mL oral solution  
EU/1/20/1491/002 120 mL oral solution  
EU/1/20/1491/003 250 mL oral solution  
EU/1/20/1491/004 360 mL oral solution

13. **BATCH NUMBER**

Lot

14. **GENERAL CLASSIFICATION FOR SUPPLY**

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

Fintepla

17. **UNIQUE IDENTIFIER – 2D BARCODE**

18. **UNIQUE IDENTIFIER - HUMAN READABLE DATA**
B. PACKAGE LEAFLET
Package leaflet: Information for the patient

Fintepla 2.2 mg/mL oral solution
fenfluramine

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you or your child may experience. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you or your child starts taking this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you or your child only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours or your child’s.
- If you or your child experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet
1. What Fintepla is and what it is used for
2. What you need to know before you take Fintepla
3. How to take Fintepla
4. Possible side effects
5. How to store Fintepla
6. Contents of the pack and other information

1. What Fintepla is and what it is used for

Fintepla contains the active substance fenfluramine.

Fintepla is used to treat seizures (fits) in patients aged 2 years and over who have a type of epilepsy called Dravet syndrome. It can help to reduce the number and severity of seizures.

It is not completely known how Fintepla works. However, it is thought to work by increasing the activity in the brain of a natural substance called serotonin, and this may reduce seizures.

2. What you need to know before you or your child takes Fintepla

Do not take Fintepla if:
- you or your child are allergic to fenfluramine or any of the other ingredients of this medicine (listed in section 6)
- you or your child have a heart problem such as ‘valve disease’ or ‘pulmonary arterial hypertension’ (high pressure in the arteries of the lungs)
- you or your child have taken medicines called monoamine oxidase inhibitors in the last 2 weeks.

Do not take Fintepla if any of the above apply to you. If you are not sure, talk to your doctor, pharmacist or nurse before taking Fintepla.

Warnings and precautions
Talk to your doctor, pharmacist or nurse before taking Fintepla if:
- you or your child have glaucoma
- you or your child have had thoughts about harming or killing yourself
• you or your child are taking a medicine called cyproheptadine, which is used to treat allergies or to improve appetite.

If any of the above applies to you or your child (or you are not sure), talk to your doctor, pharmacist or nurse before taking Fintepla.

Tests and checks
Before you or your child start taking Fintepla your doctor must check the heart with an echocardiogram (ECHO). The doctor will check that the valves in the heart work properly and the pressure in the artery between the heart and lungs is not too high. Once you or your child has started taking Fintepla, you will have an echocardiogram check every 6 months for the first 2 years and then once a year. If Fintepla treatment is stopped, you or your child will need to have an echocardiogram 6 months after the last dose.

Your doctor should also check your weight before and during your treatment as Fintepla can cause you to lose weight.

‘Serotonin syndrome’
Tell your doctor or pharmacist before taking Fintepla if you or your child are taking medicines which can increase the levels of serotonin in your brain. This is because taking these medicines and Fintepla can cause serotonin syndrome, which is a life-threatening condition. Medicines that can increase serotonin levels include:
• ‘triptans’ (such as sumatriptan) – used for migraine
• MAOI medicines – used for depression
• SSRI or SNRI medicines – used for depression and anxiety.

Look out for the signs of serotonin syndrome which include:
• being agitated, seeing things which are not there (hallucinations) or passing out
• heart and circulation problems such as fast heartbeat, blood pressure going up and down, high body temperature, sweating
• twitching muscles and being uncoordinated
• feeling or being sick and diarrhoea.

Tell your doctor straight away if you notice any of the serious side effects above.

Other medicines and Fintepla
Tell your doctor or pharmacist if you or your child are taking, have recently taken, or might take any other medicines. This is because Fintepla can affect the way some other medicines work. Also, some other medicines can affect the way Fintepla works.

Fintepla can make you or your child feel sleepy. You or your child may be even more sleepy if you take other medicines such as anti-depressants or alcohol at the same time as Fintepla.

In particular, tell your doctor or pharmacist if you or your child are taking, have recently taken, or might take:
• stiripentol, a medicine for epilepsy, as your dose of Fintepla may need to be reduced
• ‘triptans’, MAOI, SNRI or SSRI medicines – see above under ‘Serotonin syndrome’
• carbamazepine, primidone, rifampicin, phenobarbital and other barbiturates, phenytoin, and efavirenz, as your dose of Fintepla may need to be increased.

Also speak with your doctor or pharmacist if you or your child smoke as the dose of Fintepla may need to be increased.
**Pregnancy and breast-feeding**
If you or your child are pregnant, think you or your child might be pregnant, or are planning to have a baby or are breast-feeding, ask your doctor for advice before taking this medicine.

**Driving and using machines**
Talk to your doctor about driving, using machines, or if you or your child undertake activities such as cycling or other sports, because you or your child may feel sleepy after taking this medicine.

**Fintepla contains sodium ethyl p-hydroxybenzoate (E 215) and sodium methyl p-hydroxybenzoate (E 219)**
This may cause allergic reactions (possibly delayed).

**Fintepla contains sulfur dioxide (E 220)**
This may rarely cause hypersensitivity reactions and bronchospasm.

**Fintepla contains glucose**
This may be harmful to the teeth.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.

**Fintepla contains sodium**
This medicine contains less than 1 mmol sodium (23 mg) per 12 mL, that is to say essentially ‘sodium-free’.

3. **How to take Fintepla**

Always take this medicine exactly as your doctor, pharmacist or nurse has told you. Check with them if you are not sure.

**How much to take**
- You will be told how many mL to take for each dose.
- Take the medicine twice a day.
- Your doctor will start you or your child on a low dose. This can then be gradually increased depending on how well the medicine works and how it affects you or your child.
- The maximum amount you can take is 6 mL twice a day.
- If you are taking stiripentol, the maximum amount you can take is 4 mL twice a day.
- Do not take more than the prescribed dose as it may cause serious side effects.

**Taking this medicine**
- Take this medicine by mouth.
- Take the medicine with food or between meals.
- Fintepla oral solution is compatible with a ketogenic diet.
- The medicine is a liquid. Use the oral syringes provided to measure your dose, as explained below.
- Use the green 3 mL syringe for doses up to 3.0 mL.
- Use the purple 6 mL syringe for doses between 3.2 mL and 6.0 mL.
- Fintepla oral solution is compatible with most enteral feeding tubes.
- To flush the feeding tube, fill the syringe used for dosing with water and flush the tube. Do this 3 times.
3 mL syringe - green

6 mL syringe - purple
Write on the carton the date you first opened the bottle.
You must attach the bottle adaptor the first time you open the bottle. The following instructions tell you how to attach the adaptor.

**Inserting the bottle adaptor:**
When the bottle is first opened the bottle adaptor must be pushed into the bottle.
Wash and dry your hands.
Remove the bottle adaptor from its packaging.
Place the bottle on a flat, firm surface.
Open the bottle.

Hold the bottle firmly.
Line up the bottle adapter with the open top of the bottle.
Push the bottle adaptor into the bottle with your palm until the adaptor is flush with the top of the bottle.
Leave in the bottle adaptor after using the medicine.
Screw the bottle cap onto the bottle with the bottle adaptor left in.

**Taking the medicine:**
Before you measure out the dose, make sure the plunger is pushed all the way into the oral syringe.
Hold the bottle of medicine firmly on a hard, flat surface.
Push the tip of the oral syringe into the bottle adaptor until it cannot be pushed further.

Hold the oral syringe and bottle together and turn upside down.
Slowly pull the plunger to draw up the right dose.
Hold the oral syringe and bottle together and then turn over.
Holding the bottle firmly, gently pull the oral syringe out of the bottle adaptor.
Place the tip of the oral syringe against the inside of the patient’s cheek. Gently push the plunger until it is fully pressed. There will be a small volume left in the tip of the syringe. This is normal. Do not squirt the medicine into the back of the throat as this may cause choking.

Place the cap back on the bottle and turn until it stops. Always leave the adaptor in place in the bottle.

Cleaning the syringe:
Rinse the oral syringe with clean water and allow it to air dry after each use. Rinse the inside of the syringe and the plunger. Clean water can be pulled into the syringe with the plunger and pushed out several times to clean the syringe. It is okay to separate the plunger from the syringe to rinse each part. It is safe to clean the syringe and plunger in a dishwasher. The syringe and plunger must be completely dry before the next use.

If you or your child take more Fintepla than you or your child should
Talk to a doctor or go to a hospital straight away. Take the medicine bottle with you. The following effects may happen: being agitated, sleepy or confused, being flushed or hot, shivering and sweating.

If you or your child forget to take Fintepla
• Take it as soon as you remember it. However, if it is nearly time to take the next dose, skip the missed dose.
• Do not take a double dose to make up for a forgotten dose.

If you or your child stop taking Fintepla
Do not stop taking Fintepla without talking to your doctor. If your doctor decides to stop this medicine, the doctor will ask you or your child to slowly lower the amount taken each day. Slowly lowering the dose will reduce the risk of having a seizure and status epilepticus. Six months after the last dose of Fintepla, you or your child will need to have an echocardiogram.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
4. **Possible side effects**

Like all medicines, this medicine can cause side effects, although not everybody gets them.

**Very common:** may affect more than 1 in 10 people
- falling
- diarrhoea
- vomiting
- weight loss
- constipation
- loss of appetite
- high temperature
- lower blood sugar
- abnormal echocardiogram
- feeling tired, sleepy or weak
- chest infection and bronchitis
- trembling of the hands, arms or legs
- long-lasting seizures (status epilepticus)

**Common:** may affect up to 1 in 10 people
- irritability
- ear infection
- abnormal behaviour

Tell your doctor, pharmacist or nurse if you notice any of the side effects listed above.

**Reporting of side effects**
If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. **How to store Fintepla**

- Keep this medicine out of the sight and reach of children.
- Do not use this medicine after the expiry date which is stated on the carton and bottle label after EXP. The expiry date refers to the last day of that month.
- Do not refrigerate or freeze.
- Use within 3 months of first opening the bottle.
- Wash the syringe after each use.
- If you lose or damage a syringe, or cannot read the dose markings on a syringe, use another oral syringe provided in your pack, or speak to your pharmacist.
- Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

6. **Contents of the pack and other information**

**What Fintepla contains**
The active substance is called fenfluramine. Each ml contains 2.2 mg of fenfluramine (as fenfluramine hydrochloride).
The other ingredients are:
- Sodium ethyl para-hydroxybenzoate (E 215)
- Sodium methyl para-hydroxybenzoate (E 219)
• Sucralose (E 955)
• Hydroxyethylcellulose (E 1525)
• Monosodium phosphate (E 339)
• Disodium phosphate (E 339)
• Cherry flavouring powder:
  o Acacia (E 414)
  o Glucose (maize)
  o Ethyl benzoate
  o Natural flavouring preparations
  o Natural flavouring substances
  o Flavouring substances
  o Maltodextrin (maize)
  o Sulphur dioxide (E 220)
• Potassium citrate (E 332)
• Citric acid monohydrate (E 330)
• Water for injections

What Fintepla looks like and contents of the pack
• Fintepla oral solution is supplied as a clear, colourless, cherry-flavoured slightly viscous liquid.
• The solution is available in a white bottle with a child-resistant, tamper-evident cap.
• Each carton contains either:
  o Bottle containing 60 mL oral solution, a bottle adaptor, two 3 mL oral syringes with 0.1 mL graduations, and two 6 mL syringes with 0.2 mL graduations.
  o Bottle containing 120 mL oral solution, a bottle adaptor, two 3 mL oral syringes with 0.1 mL graduations, and two 6 mL syringes with 0.2 mL graduations.
  o Bottle containing 250 mL oral solution, a bottle adaptor, two 3 mL oral syringes with 0.1 mL graduations, and two 6 mL syringes with 0.2 mL graduations.
  o Bottle containing 360 mL oral solution, a bottle adaptor, two 3 mL oral syringes with 0.1 mL graduations, and two 6 mL syringes with 0.2 mL graduations.
• Not all pack sizes may be marketed in your country.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder:
Zogenix ROI Limited,
Trinity House,
Charleston Road,
Ranelagh,
Dublin 6,
D06 C8X4,
Ireland

Manufacturer:
Millmount Healthcare Ltd,
Millmount Site, Block 7,
City North Business Campus,
Stamullen,
Co. Meath,
K32 YD60
Ireland

This leaflet was last revised in

Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu. There are also links to other websites about rare diseases and treatments.